Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 7/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4439353 | 0.84 | CYP3A4 (0.58) | L3MBTL1TDP1MEN1RAB9AKMT2A | |
| Aspartic Acid SCHEMBL7370756 | 0.83 | GRIK1 (0.41) | L3MBTL1TDP1MEN1RAB9AKMT2A | |
| SCHEMBL7174243 | 0.81 | L3MBTL1 (0.52) | L3MBTL1TDP1MEN1RAB9AKMT2A | |
| SCHEMBL5663870 | 0.80 | CYP3A4 (0.53) | L3MBTL1MEN1RAB9AKMT2AALDH1A1 | |
| SCHEMBL7288587 | 0.79 | ALDH1A1 (0.50) | L3MBTL1TDP1MEN1RAB9AKMT2A | |
| SCHEMBL3487724 | 0.78 | CA12 (0.47) | TDP1MEN1RAB9AKMT2AALDH1A1 | |
| SCHEMBL3764257 | 0.77 | RAB9A (0.55) | L3MBTL1TDP1MEN1RAB9AKMT2A | |
| SCHEMBL21953403 | 0.77 | ALDH1A1 (0.48) | L3MBTL1TDP1MEN1RAB9AKMT2A | |
| SCHEMBL8493097 | 0.77 | CA12 (0.66) | L3MBTL1TDP1MEN1RAB9AKMT2A | |
| SCHEMBL11927841 | 0.76 | RAB9A (0.54) | L3MBTL1TDP1MEN1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0764167-A4 | BICYCLING LACTAM INHIBITOR OF INTERLEUKIN-1-BETA CONVERTING ENZYME | SANOFI WINTHROP INC (US) | 1997-09-17 | — | — | EP | claimed |
| EP-0764167-A1 | BICYCLING LACTAM INHIBITOR OF INTERLEUKIN-1-BETA CONVERTING ENZYME | SANOFI WINTHROP, INC. (US) | 1997-03-26 | — | — | EP | claimed |
| WO-1995033751-A1 | BICYCLING LACTAM INHIBITOR OF INTERLEUKIN-1-BETA CONVERTING ENZYME | SANOFI WINTHROP, INC. (US) | 1995-12-14 | — | — | WO | claimed |
| EP-1660464-B1 | CASPASE INHIBITORS CONTAINING ISOXAZOLINE RING | LG LIFE SCIENCES LTD (KR) | 2015-02-25 | — | — | EP | disclosed |
| US-20100105681-A1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS | LASSOIE MARIE-AGNES | 2010-04-29 | — | — | US | disclosed |
| US-7638630-B2 | Very Late Antigen-4 dependent inflammatory disease; asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, inflammatory skin disorders, autoimmune disorders, or atherosclerosis, inflammatory skin disorder; methyl 3-[2-(2,6-dichlorophenyl)-6-quinolinyl]-2-hydroxy-2-propenoate | UCB PHARMA S.A. (BE) | 2009-12-29 | — | — | US | disclosed |
| US-7557133-B2 | Caspase inhibitors containing isoxazoline ring | LG LIFE SCIENCES LTD. (KR) | 2009-07-07 | — | — | US | disclosed |
| US-20080064720-A1 | 2,6-Quinolinyl And 2,6-Naphthyl Derivatives, Processes For Preparing Them And Their Uses As Vla-4 Inhibitors | UCB, S.A. (BE) | 2008-03-13 | — | — | US | disclosed |
| US-20060223848-A1 | Caspase inhibitors containing isoxazoline ring | LG CHEM, LTD. (KR) | 2006-10-05 | — | — | US | disclosed |
| WO-2006033551-A1 | CASPASE INHIBITORS CONTAINING DICARBONYLAMINO-ISOXAZOLINE | LG LIFE SCIENCES LTD. (KR) | 2006-03-30 | — | — | WO | disclosed |
| US-6576614-B1 | Administering methyl ketones or closed hemiketal derivatives of aspartic acid | VERTEX PHARMACEUTICALS INCORPORATED | 2003-06-10 | — | — | US | disclosed |
| US-6162828-A | IMMUNOLOGY; ANTIINFLAMMATORY AGENTS; ANTITUMOR AGENTS; BONE DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-12-19 | — | — | US | disclosed |
| US-5985838-A | TREATING INFECTIOUS DISEASE, RESPIRATORY DISEASE, INFLAMMATORY CONDITIONS, IMMUNE-BASED DISEASE, AUTO-IMMUNE DISEASE, BONE DISEASE, AND TUMORS | VERTEX PHARMACEUTICALS, INC. (US) | 1999-11-16 | — | — | US | disclosed |
| WO-1998024814-A2 | N-TERMINALLY MODIFIED POLYPEPTIDE ENZYME INHIBITORS, AND RELATED THERAPEUTIC METHODS AND PHARMACEUTICAL COMPOSITIONS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1998-06-11 | — | — | WO | disclosed |
| EP-0820464-A2 | CYSTEINE PROTEASE INHIBITOR | Takeda Chemical Industries, Ltd. (JP) | 1998-01-28 | — | — | EP | disclosed |
| EP-0764167-A4 | BICYCLING LACTAM INHIBITOR OF INTERLEUKIN-1-BETA CONVERTING ENZYME | SANOFI WINTHROP INC (US) | 1997-09-17 | — | — | EP | disclosed |
| EP-0764167-A1 | BICYCLING LACTAM INHIBITOR OF INTERLEUKIN-1-BETA CONVERTING ENZYME | SANOFI WINTHROP, INC. (US) | 1997-03-26 | — | — | EP | disclosed |
| WO-1996030395-A2 | CYSTEINE PROTEASE INHIBITOR | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-10-03 | — | — | WO | disclosed |
| WO-1995033751-A1 | BICYCLING LACTAM INHIBITOR OF INTERLEUKIN-1-BETA CONVERTING ENZYME | SANOFI WINTHROP, INC. (US) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064720-A1 | 2,6-Quinolinyl And 2,6-Naphthyl Derivatives, Processes For Preparing Them And Their Uses As Vla-4 Inhibitors | VCAM1, HRH4, LTA4H | L3MBTL1 4844/4885TDP1 4765/4885MEN1 2106/4885 |
| US-20100105681-A1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS | SCN4A, NECTIN4, VPS4B | L3MBTL1 4720/4885TDP1 4364/4885MEN1 2979/4885 |
| US-20060223848-A1 | Caspase inhibitors containing isoxazoline ring | CASP1, CASP7, CASP2 | L3MBTL1 2455/4885TDP1 1505/4885MEN1 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.